Hematopoiesis & Hematologic Malignancies (HHM) Research Program

Theme 2: Hematologic Malignancies (HM)

Aim 1

Signaling of hematologic malignancies (i.e. leukemia, myeloma, lymphoma)

Aim 2

Hematologic malignancies and bone microenvironment
Utpal Davé, MD

Our patients lead us to think harder about these diseases and to generate new ideas.

Utpal Davé, MD — HHM program co-leader

Pediatric blood cancers: Reuben Kapur, PhD

HHM program co-leader Reuben Kapur, PhD, is director of the Herman B Wells Center for Pediatric Research, as well as vice chair for basic science research at IU School of Medicine’s Department of Pediatrics.

Nationally recognized for his work in pediatric blood cancers, Kapur earned two major grants—nearly $4 million in funding—for his research on juvenile myelomonocytic leukemia and acute myeloid leukemia.

His work on obesity-related inflammation and leukemia development was featured in the “Best of Session” at the 63rd American Society of Hematology (ASH) Annual Meeting in December 2021.

Meet Dr. Kapur

#ResearchCuresCancer

Support Our Research